# Culmination Bio

**Type:** venture
**Status:** Draft
**Confidence:** Medium
**Focus:** clinical data platform, longitudinal patient data, drug discovery, diagnostics, biotech spinout
**Stage:** Operating subsidiary; $10M from Amgen Ventures and Merck Global Health Innovation Fund (2023)
**Location:** St. George, UT
**Updated:** 2026-06-19
**Needs-reviewed:** 2026-06-19
**Hero:** https://picsum.photos/seed/culmination-bio-clinical-data-2026/1600/1100
**Pull:** *Forty years of Intermountain patient records — clinical, omics, tissue, and claims — organized for discovery partnerships.*
**Relates:** cites [Official Website: Culmination Bio](culmination-bio-official-website.md)

## Summary

Culmination Bio is a biotech subsidiary of Intermountain Health, launched in 2022 and based in St. George, Utah. It converts Intermountain's longitudinal patient data — clinical records, omics, tissue samples, diagnostics, claims, and EMR fields — into a platform for therapeutic-target discovery, diagnostics, and care-process insights sold through data-access and collaboration partnerships.

For the wiki, Culmination is one of Utah's clearest examples of a health-system data asset being productized outside traditional hospital quality-improvement programs. Amgen Ventures and Merck Global Health Innovation Fund backed a $10M round in 2023, signaling pharma interest in the dataset.

## Impact

Drug discovery fails often because early biological hypotheses are wrong. Longitudinal population-scale data — linking clinical outcomes to molecular measurements over decades — is one of the best available tools for forming better hypotheses. Intermountain Health operates 33 hospitals and 385 clinics across nine states; Culmination says its data lake spans 40+ years of de-identified records, more than 9 million archival clinical tissue samples, and ongoing prospective enrollment.

The counterfactual: without a dedicated spinout, much of this data would likely remain siloed inside the health system for internal quality and research projects rather than structured for external pharma discovery pipelines. A Merck collaboration focused on autoimmune disease (24 months) is one public template for how partnerships may work.

## What They Are Building

Culmination builds a searchable data platform rather than drugs directly. Discovery Cohort data is organized in Apex, the company's Intelligence Platform, where partners can query disease summaries, diagnosis counts and types, demographics, prescriptions, and patient-specific genomic overviews, then assemble custom cohorts.

The hard engineering problems sit in de-identification, record linkage, identity resolution across decades of heterogeneous EHR coding, and maintaining HIPAA and IRB compliance while preserving research utility. Linking clinical records to omics and tissue samples longitudinally requires infrastructure most health systems have not built at this scale.

## What They Need Now

Likely needs include computational biologists, clinical data scientists, bioinformaticians, health-data engineers, privacy and compliance specialists, IRB and regulatory experts, and pharma business-development leaders who understand data-licensing deals. The Intermountain parent brings institutional scale; the spinout structure is meant to move faster than a hospital QI program.

## Who Could Help

Useful helpers include health-data privacy counsel, IRB and clinical-research compliance advisors, pharma partnership strategists, bioinformatics platform engineers, and investors with experience in real-world-evidence and data-platform businesses.

## Utah Context

Culmination extends a long Utah thread in health-data infrastructure. Intermountain's [clinical quality-improvement work](intermountain-clinical-quality-improvement.md) showed how an integrated regional system could treat care delivery as an engineering problem; Culmination applies a different commercial lens to the same institutional data advantage.

The spinout also sits near Utah's broader life-sciences cluster — companies such as [Myriad Genetics](myriad-genetics.md), [BioFire Diagnostics](biofire-diagnostics.md), and [Huntsman Cancer Institute](huntsman-cancer-institute.md) — though Culmination's model is platform licensing rather than diagnostic kits or therapeutic development.

## Evidence

- [Official Website: Culmination Bio](culmination-bio-official-website.md)

## See Also

- [Intermountain Clinical Quality Improvement](intermountain-clinical-quality-improvement.md) — historical Intermountain delivery-science work that shares the parent health system's data-and-process culture.
- [Myriad Genetics](myriad-genetics.md) — Utah molecular diagnostics company; adjacent life-sciences context.
- [Huntsman Cancer Institute](huntsman-cancer-institute.md) — major Utah oncology research institution.

## Open Questions

- Which partnership terms, cohort sizes, and hypothesis-validation outcomes from Merck, Amgen, or other pharma collaborators are publicly verifiable?
- How representative is Intermountain's Intermountain West patient population for generalizable drug-discovery use cases, especially for population-specific biology?
- What governance constraints does Intermountain Health's nonprofit parent place on Culmination's commercial independence?
- Should the Intermountain launch announcement and Amgen/Merck backing be captured as dedicated wiki source pages?
- The placeholder hero should be replaced with a cleared facilities or data-platform image when rights are confirmed.